Treating Hepatobiliary Cancer: The Immunologic Approach
Authors:
- A.G. DuffyADA.G. Duffy
- T.F. GretenTGT.F. Greten
- 3 May 2017
- journal article
- research article
- Published by S. Karger AG in Digestive Diseases
- Vol. 35 (4) , 390-396
Abstract
Hepatobiliary cancer comprises a heterogeneous group of malignancies in which the standard treatments for advanced disease are minimally effective and evolve slowly over time. Like the majority of gastrointestinal cancers, with some notable exceptions, the impact of immune-based approaches is yet to be experienced. Notwithstanding this, the etiological background of hepatobiliary cancer - overlapping in almost every known causative or associated factor with inflammation - provides a strong clue that these approaches may have an impact on this group of diseases. This review seeks to put the management of hepatobiliary cancers in the context of its inflammation-based etiology, with the aim of pointing to the therapeutic opportunities in immune-based approaches currently entering the clinic or those that are about to do so.Keywords
This publication has 61 references indexed in Scilit:
- Genomic spectra of biliary tract cancerNature Genetics, 2015
- Association of Aflatoxin With Gallbladder Cancer in ChileJAMA, 2015
- Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancerJournal of Translational Medicine, 2014
- Prognostic impact of tumour-infiltrating immune cells on biliary tract cancerBritish Journal of Cancer, 2013
- Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract CancerJournal of Gastrointestinal Surgery, 2013
- Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular CarcinomaPLOS ONE, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Interaction of B7‐H1 on intrahepatic cholangiocarcinoma cells with PD‐1 on tumor‐infiltrating T cells as a mechanism of immune evasionJournal of Surgical Oncology, 2009
- Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastasesWorld Journal of Gastroenterology, 2006
- Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracilEuropean Journal of Cancer, 1997